Rezdiffra (resmetirom) is a medication approved by the U.S. Food and Drug Administration (FDA) for specific medical conditions. 

Rezdiffra (Resmetirom) Prescribing Information: A Comprehensive Overview

Rezdiffra (resmetirom) is a medication approved by the U.S. Food and Drug Administration (FDA) for specific medical conditions. This article provides a comprehensive overview of key prescribing information for Rezdiffra, intended for informational purposes only. It is crucial to understand that this content does not substitute for professional medical advice, diagnosis, or treatment from a qualified healthcare provider. Always consult with your doctor or pharmacist regarding any medical conditions or before making any decisions about your health or treatment.

What is Rezdiffra?

Rezdiffra (resmetirom) is a thyroid hormone receptor-beta (THR-β) agonist. It is indicated for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (stages F2-F3), in conjunction with diet and exercise. NASH, now often referred to as metabolic dysfunction-associated steatohepatitis (MASH), is a serious form of fatty liver disease that can lead to liver damage and cirrhosis.

Indications and Usage

Rezdiffra is specifically indicated for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (F2-F3). Its approval is based on improvements in liver histological endpoints. It is not indicated for patients with compensated or decompensated cirrhosis, or for patients without moderate to advanced fibrosis.

Important Dosing and Administration

Recommended Dosage

The recommended dosage of Rezdiffra is typically 80 mg or 100 mg orally once daily. The dose may be adjusted by a healthcare professional based on individual patient factors, liver function, and tolerability. Always follow the specific instructions provided by your prescribing doctor.

Administration Instructions

Rezdiffra should be taken orally once daily. It can be taken with or without food. Patients should be advised to take the medication around the same time each day to maintain consistent drug levels. If a dose is missed, it should be taken as soon as possible on the same day, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped. Do not double doses to make up for a missed one.

Contraindications

Rezdiffra is contraindicated in patients with:

• Decompensated cirrhosis.


• End-stage liver disease (ESLD).


• Acute liver failure.


• Severe hepatic impairment (Child-Pugh C).

Use in these populations can lead to increased exposure to resmetirom and potentially increase the risk of adverse reactions due to impaired drug clearance.

Warnings and Precautions

Liver-Related Adverse Reactions

Transient elevations in liver transaminases (ALT and AST) have been observed in clinical trials. Liver function tests should be monitored periodically during treatment with Rezdiffra, and more frequently if clinically indicated. If significant elevations occur, the dosage may need to be reduced or the treatment temporarily interrupted or discontinued.

Gallbladder-Related Adverse Reactions

Treatment with Rezdiffra may increase the risk of gallbladder-related adverse reactions, including cholelithiasis (gallstones) and cholecystitis. Patients should be monitored for symptoms of gallbladder disease, such as sudden and severe pain in the upper right abdomen.

Drug Interactions

Resmetirom is a substrate of various drug metabolizing enzymes and transporters. Co-administration with certain medications can alter the exposure of resmetirom or the co-administered drug. Healthcare professionals should review all concomitant medications to identify potential interactions. Notable interactions include those with strong CYP2C8 inhibitors (e.g., gemfibrozil), which can significantly increase resmetirom exposure, and OATP1B1/1B3 inhibitors (e.g., certain statins), which may also affect drug levels.

Adverse Reactions

The most common adverse reactions reported in clinical trials (incidence ≥5% and greater than placebo) include:

• Nausea


• Diarrhea


• Abdominal pain


• Upper respiratory tract infections


• Constipation


• Pruritus (itching)

Other less common but important adverse reactions may also occur. Patients should report any new or worsening symptoms to their healthcare provider promptly.

Use in Specific Populations

Hepatic Impairment

Dose adjustments may be necessary for patients with moderate hepatic impairment (Child-Pugh B). Rezdiffra is contraindicated in severe hepatic impairment (Child-Pugh C) and decompensated cirrhosis due to the risk of increased resmetirom exposure and potential adverse events.

Renal Impairment

No dose adjustment is generally recommended for patients with mild to moderate renal impairment. Data for severe renal impairment or end-stage renal disease (ESRD) is limited, and caution should be exercised in these populations.

Pregnancy and Lactation

There is insufficient data on Rezdiffra use in pregnant women to inform a drug-associated risk. The decision to use Rezdiffra during pregnancy should balance potential benefits to the mother and potential risks to the fetus. It is unknown whether resmetirom is excreted in human milk. Consideration should be given to the developmental and health benefits of breastfeeding versus the mother's clinical need for Rezdiffra and any potential adverse effects on the breastfed infant.

Pediatric Use

The safety and effectiveness of Rezdiffra in pediatric patients have not been established. Rezdiffra is not indicated for use in individuals under 18 years of age.

This overview summarizes key prescribing information for Rezdiffra. For complete, detailed, and up-to-date information, always refer to the official full prescribing information (package insert) provided by the manufacturer or consult a qualified healthcare professional. This information is not a substitute for professional medical advice.